Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + albumin-bound paclitaxel + gemcitabine
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Sintilimab + albumin-bound paclitaxel + gemcitabine is an investigational chemoimmunotherapy combination regimen being evaluated for the treatment of advanced malignancies. The regimen consists of **sintilimab** (Tyvyt), a fully human IgG4 monoclonal antibody that targets the Programmed Death-1 (PD-1) receptor to inhibit immune checkpoint signaling and restore T-cell antitumor activity; **albumin-bound paclitaxel** (nab-paclitaxel; Abraxane), a nanoparticle formulation of the taxane paclitaxel that disrupts microtubule dynamics to inhibit cell division; and **gemcitabine**, a nucleoside analog that interferes with DNA synthesis. This combination, often referred to as sintilimab plus the AG backbone, is primarily being studied as a first-line therapy for unresectable locally advanced or metastatic biliary tract cancers (BTC), including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer. The strategy leverages the synergistic potential of combining cytotoxic chemotherapy with PD-1 blockade to improve objective response rates and survival outcomes in patients with biliary tract malignancies.
- Brand names
- Abraxane
- Other names
- sintilimab + nab-paclitaxel + gemcitabinesintilimab + AG regimen
02
Targets
DNA polymerase familyPDCD1 (Programmed cell death protein 1 receptor)RNR (Ribonucleotide reductase)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on sintilimab + albumin-bound paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + albumin-bound paclitaxel + gemcitabine.